共 50 条
Targeting IL-4 for the Treatment of Atopic Dermatitis
被引:0
|作者:
Chiricozzi, Andrea
[1
,2
]
Maurelli, Martina
[3
]
Peris, Ketty
[1
,2
]
Girolomoni, Giampiero
[3
]
机构:
[1] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Med & Chirurg, Dermatol, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dermatol, Rome, Italy
[3] Univ Verona, Dept Med, Sect Dermatol, Verona, Italy
关键词:
atopic dermatitis;
IL-4;
inhibitor;
dupilumab;
pascolizumab;
pitrakinra;
TH2;
CYTOKINES;
STAPHYLOCOCCUS-AUREUS;
DERMAL FIBROBLASTS;
DENDRITIC CELLS;
TRANSGENIC MICE;
LESIONAL SKIN;
UP-REGULATION;
IFN-GAMMA;
IN-VITRO;
T-CELLS;
D O I:
暂无
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)-4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4.
引用
收藏
页码:151 / 156
页数:6
相关论文